Dilazep dihydrochloride; clinical evaluation of its effect on attacks of vertigo in Meniere's disease.

概要

論文の詳細を見る
Comelian® (dilazep dihydrochloride) was used for six months to treat 80 patients with Meniere's disease, and its effectiveness in preventing attacks of vertigo and its safety were evaluated.1) The average number of definitive spells per month was reduced significantly (p>0.001) from 1.45±0.21 (Mean±S. D.) for six months before the start of treatment to 0.65±0.12 during the six month treatment.2) The maximum interval between definitive attacks was prolonged significantly (p<0.001) from 69.1±5.6 days for six months before the start of treatment to 120.3±5.8 days during the six month treatment.3) The effect of treatment was evaluated by comparing the incidence of vertigo before and after treatment. Complete control of definitive spells was observed in 23 patients (28.8%), substantial control in 30 (37.5%), and limited control in 7 (8.7%).4) The global improvement rate was 57.5% for moderate or greater improvement and 78.8% for slight improvement or more.5) An adverse reaction was observed in only one patient (rash).6) The usefulness of dilazep was rated as 58.8% moderately useful or better and 80% slightly useful or better.It is concluded that long term administration of Comeliane is very safe and that it is a very useful drug for patients with Meniere's disease.
耳鼻咽喉科臨床学会の論文